Treatment Options for Uncomplicated Community-Acquired Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus: Oral Antimicrobial Agents

2008 ◽  
Vol 9 (s1) ◽  
pp. s29-s34 ◽  
Author(s):  
Marcus Zervos
Keyword(s):  
Staphylococcus Aureus ◽  
Soft Tissue ◽  
Antimicrobial Agents ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Treatment Options ◽  
Soft Tissue Infections ◽  
Methicillin Resistant

Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections

2020 ◽  
Vol 19 (3) ◽  
pp. 236-241 ◽  
Author(s):  
Vasilios Petrakis ◽  
Periklis Panagopoulos ◽  
Nikolaos Papanas
Keyword(s):  
Staphylococcus Aureus ◽  
Soft Tissue ◽  
Antimicrobial Agents ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Antimicrobial Treatment ◽  
Soft Tissue Infections ◽  
Gram Positive ◽  
Positive Skin ◽  
Methicillin Resistant ◽  
Complicated Skin

New antimicrobial agents have been developed to treat infections caused by methicillin-resistant Staphylococcus aureus and other multidrug-resistant pathogens. Dalbavancin is a novel semisynthetic lipoglycopeptide antibiotic, particularly active against methicillin-resistant Staphylococcus aureus. Due to its unique pharmacological characteristics and longer half-life, it can be administered once-weekly or every 15 days and in outpatient setting. Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.

Sign in / Sign up

Export Citation Format

Share Document